Accuray (ARAY) Stock Price, News & Analysis

Company Overview

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue. The CyberKnife platform is widely used for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), supporting treatments across a range of tumor types and anatomical sites. The TomoTherapy and Radixact systems incorporate integrated imaging, adaptive planning and dose-shaping capabilities that support daily adjustments in treatment delivery, helping to improve patient outcomes and operational efficiency in oncology centers.

Founded in 1990 and headquartered in Madison, Wisconsin, Accuray serves a broad network of hospitals, cancer centers and research institutions in North America, Europe, Asia-Pacific and other regions. The company maintains additional offices and service centers in locations such as Sunnyvale, California; Milan, Italy; and Singapore to support its global customer base. Since September 2017, Accuray has been led by President and Chief Executive Officer Peter C. Arduini, whose background in medical technology and healthcare operations has guided the company’s focus on product innovation and clinical collaboration.

Key Stats

• Today's Range: $0.32 to $0.35
• 50-Day Range: $0.27 to $0.48
• 52-Week Range: $0.25 to $2.10
• Volume: 1.48 million shs
• Average Volume: 4.17 million shs
• Market Capitalization: $39.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Reduce

Accuray Stock Analysis - MarketRank™

Accuray scored higher than 50% of companies evaluated by MarketBeat, and ranked 485th out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Accuray has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Accuray has a consensus price target of $2.00, representing about 496.3% upside from its current price of $0.34.

Amount of Analyst Coverage

Accuray has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Accuray is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Accuray is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Accuray has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.11% of the float of Accuray has been sold short.

Short Interest Ratio / Days to Cover

Accuray has a short interest ratio ("days to cover") of 0.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Accuray has recently increased by 22.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Accuray does not currently pay a dividend.

Dividend Growth

Accuray does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Accuray has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Accuray this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for ARAY on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

8 people have added Accuray to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Accuray insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.36% of the stock of Accuray is held by insiders.

Percentage Held by Institutions

64.08% of the stock of Accuray is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 6/16/2026
• Fiscal Year End: 6/30/2026
• Next Earnings (Estimated): 8/19/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:ARAY
• CIK: 1138723
• Web: www.accuray.com
• Phone: (408) 716-4600
• Fax: 408-716-4601
• Employees: 1,040
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Accuray: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: +496.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.59 million
• Net Margins: -10.76%
• Pretax Margin: -10.19%
• Return on Equity: -79.43%
• Return on Assets: -10.38%

Debt

• Debt-to-Equity Ratio: 3.21
• Current Ratio: 1.42
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $458.51 million
• Price / Sales: 0.09
• Cash Flow: $0.05 per share
• Price / Cash Flow: 7.22
• Book Value: $0.72 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 118,960,000
• Free Float: 113,777,000
• Market Cap: $39.90 million
• Optionable: Optionable
• Beta: 1.35